Schizophrenia Research
Volume 53, Issue 3 , Pages 239-248 , 15 January 2002

Does cognitive function improve with quetiapine in comparison to haloperidol?

  • Dawn.I. Velligan

      Affiliations

    • Department of Psychiatry, University of Texas Health Science Center at San Antonio, M.S.7792, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900, USA
    • Clinical Research Unit, San Antonio State Hospital, San Antonio, TX, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Psychiatry, University of Texas Health Science Center at San Antonio, M.S.7792, 7703 Floyd Curl Dr., San Antonio, TX 78229-3900, USA. Tel.: +1-210-567-5508; fax: +1-210-567-1291
    • ,
  • John Newcomer

      Affiliations

    • Washington University, St Louis, MO, USA
    • ,
  • Joseph Pultz

      Affiliations

    • Parexel International, Media, PA, USA
    • ,
  • John Csernansky

      Affiliations

    • Washington University, St Louis, MO, USA
    • ,
  • Anne L. Hoff

      Affiliations

    • Napa State Hospital, University of California, Davis, CA, USA
    • ,
  • Roderick Mahurin

      Affiliations

    • University of Washington, Seattle, WA, USA
    • ,
  • Alexander.L. Miller

      Affiliations

    • Department of Psychiatry, University of Texas Health Science Center at San Antonio, M.S.7792, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900, USA
    • Clinical Research Unit, San Antonio State Hospital, San Antonio, TX, USA

Received 15 December 1999 ,Accepted 3 June 2001.

References 

  1. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group . Multiple fixed doses of Seroquel (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatry. 1997;42:233–246
  2. Arvanitis, L.A., Rak, I.W., 1998. Efficacy, safety and tolerability of Seroquel (Quetiapine) in elderly subjects with psychotic disorders. Presented at a meeting of the American Psychiatric Association, Toronto, Canada.
  3. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr. Bull. 1990;16:477–499
  4. Fleming K, Goldberg TE, Binks S, Randolph C, Gold JM, Weinberger DR. Visuospatial working memory in patients with schizophrenia. Biol. Psychiatry. 1997;41:43–49
  5. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr. Clin. North Am. 1993;16:295–312
  6. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar DS, et al. The effect of Clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 1993;162:43–48
  7. Goldberg TE, Weinberger DR. The effects of clozapine on neurocognition: an overview. J. Clin. Psychiatry. 1994;55:88–90
  8. Goldsamt LA, Barrows J, Schwarts BJ, Weinstein C, Iqbal N. Neuropsychological correlates of schizophrenia. Psychiatr. Ann. 1993;23:151–158
  9. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153:361–369
  10. Green, M.F.,1999. The next phase of clinical trials. Presented at the Mt Sinai Conference on Cognition and Schizophrenia. Santa Fe, New Mexico, April. 1999.
  11. Green MF, Satz P, Ganzell S, Vaclav JF. Wisconsin card sorting test performance in schizophrenia: remediation of a stubborn deficit. Am. J. Psychiatry. 1992;146:62–66
  12. Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, et al. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?. Am. J. Psychiatry. 1997;154:799–804
  13. Heaton RK, Crowley TH. Effects of psychiatric disorders and their somatic treatments on neuropsychological results. In:  Filskov SD,  Boll TJ editor. Handbook of Clinical Neuropsychology. New York: John Wiley and Sons; 1981;
  14. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am. J. Psychiatry. 1992;149:898–903
  15. Kalali, A.H., Hellewell, J.S.E., Goldstein, J.M., Langham, S., 1998. A multinational survey of patient satisfaction with long-term quetiapine fumarate treatment. Presented at a meeting of the American Psychiatric Association, Toronto, Canada.
  16. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A Positron Rmission Tomography Study of Quetiapine in Schizophrenia. Arch. Gen. Psychiatry. 2000;57:553–559
  17. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response and side effects: A double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 2000;157(2000):514–520
  18. Lezak MD. Neuropsychological Assessment. 3rd ed.. New York: Oxford University Press; 1995;
  19. Meats P. Quetiapine (Seroquel); an effective and well-tolerated atypical antipsychotic. Int. J. Psychiatr. Clin. Pract. 1997;1:231–239
  20. Meltzer H. Dimensions of outcome with clozapine. Br. J. Psychiatry. 1992;160 (suppl.17):46–53
  21. Meltzer HY, Thompson PA, Lee MA. Neuropsychological deficits in schizophrenia-relation to social function and effect of anti-psychotic drug treatment. Neuropsychopharmacology. 1996;14:27S–33S
  22. Mitrushina MN, Kyle BB, D'Elia LF. Handbook of Normative Data for Neuropsychological Assessment. Oxford: Oxford University Press; 1999;
  23. Morice R, Delahunty A. Frontal/executive impairments in schizophrenia. Schizophr. Bull. 1996;22:125–137
  24. Mortimer AM. Cognitive function in schizophrenia — do neuroleptics make a difference?. Pharmacol. Biochem. Behav. 1996;56:789–795
  25. Newcomer JW. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmcology. 1999;20:106–118
  26. Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr. Bull. 1984;10:160–203
  27. Overall GE. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol. Bull. 1988;24:97–99
  28. Purdon SE, Jones DW, Stip E, labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch. Gen. Psychiatry. 2000;57:249–258
  29. Saykin AJ, Shtasel DL, Gur RE, Kester DB, et al.  Neuropsychological deficits in neuroleptic naı̈ve patients with firs-episode schizophrenia. Arch. Gen. Psychiatry. 1994;51(2):124–131
  30. Sharma T, Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 1998;18 (2, suppl. 1):12s–19s
  31. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970;45 (suppl. 212):11–19
  32. Stip E, Lussier I, Gabai M, Babai M, Fabian JL, Link C. Seroquel and cognitive improvement in patients with schizophrenia. Biol. Psychiatry. 1996;40:434–435
  33. Tandon R, Milner K, Jibson MD. Antipsychotics from theory to practice: Integrating Clinical and Basic Data. J. Clin. Psychiatry. 1999;60 (suppl. 9):21–28
  34. Velligan DI, Bow-Thomas CC. Executive function in schizophrenia. Semin. Clin. Neuropsychiatry. 1999;40:24–33
  35. Velligan DI, Mahurin RK, Diamond PL, Hazleton BC, Eckert SL, Miller AL. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997;25:21–31
  36. Waddington JL, Youssef JA, Kinsella A. Cognitive dysfunction in schizophrenia followed up over five years, and its longitudinal relationship to the emergence of tardive dyskinesia. Psychol. Med. 1990;20:835–842

PII: S0920-9964(01)00268-7

Schizophrenia Research
Volume 53, Issue 3 , Pages 239-248 , 15 January 2002

Article Tools

* Image Usage & Resolution